You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Approximately 30% of all AML cases are made up of secondary AML (sAML) subtypes t-AML and AML-MRC and are associated with a poor prognosis1-3

Therapy-related AML (t-AML): ~4% to 10% of all AML cases1,2

WHO defines t-AML as AML that arises from prior cytotoxic therapy or ionizing radiotherapy for an unrelated disease or prior cancer4,5

Prior malignancies associated with t-AML3,a

Prior malignancies associated with therapy related aml (t-aml)

AML with myelodysplasia-related changes (AML-MRC): ~25% of all AML cases1

WHO defines AML-MRC as ≥20% blasts in the peripheral blood or bone marrow and ANY of the following4,6:

It is critical to identify sAML prior to treatment3

A patient’s medical history or further testing can reveal an sAML diagnosis7

For patients with MDS or MDS/MPN, proactive monitoring of peripheral blood counts, along with bone marrow morphology, can help identify changes that suggest progression to AML8

Approximately 78% of patients with AML-MRC DO NOT present with a documented history of MDS or MDS-MPN and may require further morphologic and genetic analyses for an accurate diagnosis7,9

Among the most common genetic abnormalities found in the unfavorable cytogenetic risk group in AML are -7/del(7q) and -5/del(5q)10,11

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.